Managing side effects during dose escalation Gastrointestinal side effects are the primary challenge during retatrutide dose escalation
The new trials also strengthen the evidence that GLP-1 weight loss requires continued use, which has been a source of criticism, even though continued use is normal for most other medications for chronic diseases
doi:10.1146/annurev.bi.57.070188.001401
Side effects: Semaglutide commonly causes nausea, constipation, and diarrhea, as well as vomiting (which 24 percent of Wegovy patients reported in one study), all side effects that usually go away after a month or two
In-patient hospitalization is the most severe form of care, which provides patients with additional support, structure, medical care, and monitoring
Both the Wegovy pill and shot contain the same active ingredient semaglutide , a GLP-1 receptor agonist that works by reducing hunger, improving satiety, and promoting weight loss